+DayWeekMonth−
Tuesday · Nov 10, 2026 · Health Digest · science

FDA approves EMD Serono's Pimjetmi for a rare joint tumor

In the MANEUVER trial, 56% of patients taking pimicotinib 50 mg once daily had a tumor response at week 25, compared with 3.2% on placebo, according to the FDA. Patients on the drug also had gains in joint range of motion and reductions in worst pain, the agency said. The ASCO Post also reported the approval.

The most common side effects included itching, rash, facial swelling, fatigue, nausea and headache, and the label carries warnings for liver toxicity and harm to a developing fetus, the FDA said.

Why it matters: The FDA said the drug had fast track and breakthrough therapy designations and was reviewed together with regulators in Australia, Canada, Israel, Switzerland and the United Kingdom.

References

  1. FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
    U.S. Food and Drug Administration · fda.gov · 2026-11-10
  2. FDA Approves Pimicotinib for Symptomatic TGCT
    The ASCO Post · ascopost.com · 2026-11-10